<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985907</url>
  </required_header>
  <id_info>
    <org_study_id>04262</org_study_id>
    <secondary_id>NCI-2011-01238</secondary_id>
    <nct_id>NCT00985907</nct_id>
  </id_info>
  <brief_title>Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma</brief_title>
  <acronym>DMV</acronym>
  <official_title>Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The median overall survival (OS) of relapsed/refractory multiple myeloma (MM) is less than
      nine months. However, phase II data with the proteasome inhibitor bortezomib (Velcade®) has
      been heartening, with 35% overall response rates and median survival of 16 months. In-vitro
      data has shown that this agent dramatically increases the sensitivity to chemotherapeutic
      agents. Liposomal doxorubicin (Doxil), melphalan, and bortezomib all have different
      mechanisms of action and toxicity profiles. Clinical studies employing two drug combinations
      with these agents in patients with refractory MM have found favorable efficacy (nearly no
      progression of disease) and tolerance data. Thus, the investigators are initiating a phase
      I/II study to examine the safety and efficacy of combining all three agents into the regimen
      DMV (Doxil® + melphalan + Velcade).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2

      Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2

      Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2

      Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2

      Adjunctive therapy with a bisphosphonate, either pamidronate or zoledronic acid, will be
      given monthly.

      Dose Escalation Schedule: Dose escalation will occur only after patients have completed at
      least two cycles at a given dose level.

        1. If 0/3 experience DLT (as defined in attachment Section 6.0), the next three patients
           will be escalated by one dose level.

        2. If 1/3 experience DLT, 3 additional patients enrolled at this dose level.

             -  If 0, 1, or 2 of these additional patients experience DLT (i.e. total 3/6), the
                dose will be escalated.

             -  If 3/3 experience DLT (i.e. total 4/6) then the next lower dose will be considered
                the MTD..

        3. If 2/3 experience DLT, 3 additional patients enrolled at this dose level.

             -  If 0 or 1 of these additional patients experience DLT (i.e. total 3/6), the dose
                will be escalated.

             -  If 2 or more/3 experience DLT (i.e. total more than 3/6) then the next lower dose
                level is MTD
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low Accrual
  </why_stopped>
  <start_date type="Actual">October 28, 2004</start_date>
  <completion_date type="Actual">January 12, 2010</completion_date>
  <primary_completion_date type="Actual">October 7, 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicities (DLT) (Phase 1)</measure>
    <time_frame>Up to 2 cycles of treatment, approximately 56 days</time_frame>
    <description>Safety assessments will be evaluated as the proportion of patients experiencing the following: treatment-related grade 3 or higher toxicity (hematologic and nonhematologic) and treatment-related death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) (Phase 1)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The MTD will be considered the dose below where &lt;= 3 patients experience a DLT and the dose that two cycles can be given without meeting toxicity criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of All Treatment-related Toxicities at the MTD (Phase 1)</measure>
    <time_frame>5 years</time_frame>
    <description>NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3 will be used to determine all treatment related toxicities at the MTD. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>At each cycle, participants will be assessed for treatment response: Complete Response (CR), Near CR(nCR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD), or Progressive Disease (PD) on at least 2 measurements at minimum of a 4 week interval. The overall response rate will use the best response of CR, nCR, PR, MR, or SD. In order to qualify for responses, the following events may NOT have occurred - new/increased size of plasmacytomas or bone lesions, recurrence or persistence of hypercalcemia. Collapse of bony structure from previous disease will not constitute progression or failure to respond. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (Phase 2)</measure>
    <time_frame>28 days</time_frame>
    <description>Efficacy of DMV as determined by time to first observed response. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (Phase 2)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Efficacy of DMV as determined by progression free survival. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Phase 2)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Overall survival is defined as the amount of time from start of study therapy until death, or study completion. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Patient Participation</condition>
  <arm_group>
    <arm_group_label>Doxil® + Melphalan + Velcade (DMV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxil, melphalan, bortezomib</intervention_name>
    <description>Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2</description>
    <arm_group_label>Doxil® + Melphalan + Velcade (DMV)</arm_group_label>
    <other_name>Doxil, melphalan, Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Disease Characteristics:

          1. Patient previously diagnosed with multiple myeloma; Durie-Salmon Stage I, II, or III
             based on standard criteria

          2. Progressive disease. For non-secretory multiple myeloma, progressive disease is
             defined as bone marrow biopsy with &gt; 25% increase in plasma cells or an absolute
             increase of at least 10% over prior known level. Alternatively, development of new or
             worsening of existing lytic bone lesions or soft tissue plasmacytomas, or
             hypercalcemia (serum calcium &gt;11.5 mg/dL), or relapse from complete response.

        Patient Characteristics:

          1. 18 yrs or older

          2. Patient has given voluntary written informed consent.

          3. Unless post-menopausal or surgically sterilized, a female must be willing to use an
             acceptable method of birth control

          4. Male patient must agree to use an acceptable method for contraception for the duration
             of the study.

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.

          6. Life expectancy is at least 3 months.

          7. • Absolute Neutrophil Count (ANC) over 1,000/ul without the use of colony stimulating
             factors

               -  Platelets over 50,000/ul without transfusion support 7 days

               -  Bilirubin 2.0 mg/dl or less

               -  aspartate aminotransferase (AST) 4 times or less upper limit normal Prior Therapy
                  for Multiple Myeloma: Patients must have had at least 2 prior therapeutic
                  regimens

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  History of allergic reaction to compounds containing boron or mannitol.

          -  Active uncontrolled viral (including HIV), bacterial, or fungal infection.

          -  Grade III or IV toxicity due to previous anti-neoplastic therapy

          -  More than Grade 2 motor or sensory neuropathy

          -  Myocardial infarction within 6 months of enrollment or New York Heart Association
             (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled
             arrhythmias, or electrocardiographic evidence of acute ischemia.

          -  For any patients whose lifetime cumulative doxorubicin dose exceeds 400mg/m2, patients
             with left ventricular ejection fraction (LVEF) less than 35% by multigated acquisition
             (MUGA) .

          -  Concurrent administration of liposomal doxorubicin, melphalan, and bortezomib (single
             or two drug combinations of these are permissible)

          -  Less than 3 weeks since most recent chemotherapy or concurrent chemotherapy

          -  Use of corticosteroids (mroe than 10 mg prednisone/day or equivalent)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 25, 2009</study_first_submitted>
  <study_first_submitted_qc>September 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2009</study_first_posted>
  <results_first_submitted>May 15, 2020</results_first_submitted>
  <results_first_submitted_qc>June 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 17, 2020</results_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myeloma</keyword>
  <keyword>DMV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Arms/Groups are not separated by individual cohorts within Phase 1 as information was lost when it was transferred from our legacy system. Paper records were lost in a flood, so participants were only grouped electronically by which phase they were enrolled. The study was terminated and participants were not enrolled in Phase 2 part of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 1</title>
          <description>Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Arms/Groups are not separated by individual cohorts within Phase 1 as the information was lost when it was transferred from our legacy system. Paper records were lost in a flood. So the participants were only grouped electronically by which phase they were enrolled</population>
      <group_list>
        <group group_id="B1">
          <title>Doxil® + Melphalan + Velcade (DMV)</title>
          <description>Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>30-39 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicities (DLT) (Phase 1)</title>
        <description>Safety assessments will be evaluated as the proportion of patients experiencing the following: treatment-related grade 3 or higher toxicity (hematologic and nonhematologic) and treatment-related death.</description>
        <time_frame>Up to 2 cycles of treatment, approximately 56 days</time_frame>
        <population>Only data for Phase 1, Cohort 1 DLT was collected</population>
        <group_list>
          <group group_id="O1">
            <title>Doxil® + Melphalan + Velcade (DMV)</title>
            <description>Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicities (DLT) (Phase 1)</title>
          <description>Safety assessments will be evaluated as the proportion of patients experiencing the following: treatment-related grade 3 or higher toxicity (hematologic and nonhematologic) and treatment-related death.</description>
          <population>Only data for Phase 1, Cohort 1 DLT was collected</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) (Phase 1)</title>
        <description>The MTD will be considered the dose below where &lt;= 3 patients experience a DLT and the dose that two cycles can be given without meeting toxicity criteria.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Doxil® + Melphalan + Velcade (DMV)</title>
            <description>Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) (Phase 1)</title>
          <description>The MTD will be considered the dose below where &lt;= 3 patients experience a DLT and the dose that two cycles can be given without meeting toxicity criteria.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All Treatment-related Toxicities at the MTD (Phase 1)</title>
        <description>NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3 will be used to determine all treatment related toxicities at the MTD. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
        <time_frame>5 years</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Doxil® + Melphalan + Velcade (DMV)</title>
            <description>Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Treatment-related Toxicities at the MTD (Phase 1)</title>
          <description>NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3 will be used to determine all treatment related toxicities at the MTD. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>At each cycle, participants will be assessed for treatment response: Complete Response (CR), Near CR(nCR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD), or Progressive Disease (PD) on at least 2 measurements at minimum of a 4 week interval. The overall response rate will use the best response of CR, nCR, PR, MR, or SD. In order to qualify for responses, the following events may NOT have occurred - new/increased size of plasmacytomas or bone lesions, recurrence or persistence of hypercalcemia. Collapse of bony structure from previous disease will not constitute progression or failure to respond. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Doxil® + Melphalan + Velcade (DMV)</title>
            <description>Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>At each cycle, participants will be assessed for treatment response: Complete Response (CR), Near CR(nCR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD), or Progressive Disease (PD) on at least 2 measurements at minimum of a 4 week interval. The overall response rate will use the best response of CR, nCR, PR, MR, or SD. In order to qualify for responses, the following events may NOT have occurred - new/increased size of plasmacytomas or bone lesions, recurrence or persistence of hypercalcemia. Collapse of bony structure from previous disease will not constitute progression or failure to respond. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response (Phase 2)</title>
        <description>Efficacy of DMV as determined by time to first observed response. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
        <time_frame>28 days</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Doxil® + Melphalan + Velcade (DMV)</title>
            <description>Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response (Phase 2)</title>
          <description>Efficacy of DMV as determined by time to first observed response. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (Phase 2)</title>
        <description>Efficacy of DMV as determined by progression free survival. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Doxil® + Melphalan + Velcade (DMV)</title>
            <description>Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (Phase 2)</title>
          <description>Efficacy of DMV as determined by progression free survival. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Phase 2)</title>
        <description>Overall survival is defined as the amount of time from start of study therapy until death, or study completion. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Doxil® + Melphalan + Velcade (DMV)</title>
            <description>Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Phase 2)</title>
          <description>Overall survival is defined as the amount of time from start of study therapy until death, or study completion. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 years</time_frame>
      <desc>Arms are not separated by individual cohorts within Phase 1 as information was lost when it was transferred from legacy system. When legacy patient data was transferred, it was decided that only mortality and serious adverse event data should be retained and transferred. Other adverse event (AE) data was not electronically transferred. Paper records were lost in a flood, so participants AE data could not be recovered. The study was terminated and participants not enrolled in Phase 2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1 Doxil® + Melphalan + Velcade (DMV)</title>
          <description>Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment was terminated early due to low accrual in Phase 1. No participants were enrolled in Phase 2. Participant flow, baseline, and adverse event data was electronically transferred from a legacy clinical trials database by phase group only.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Thomas Martin, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 353-9365</phone>
      <email>Tom.Martin@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

